Investors & Media Investors & Media

What’s new.

Analyst reports

Analyst reports.

November 14th 2024

Baird - INSIGHT-003 Data Adds Support for Efti in NSCLC Ahead of Phase 3; Rated OP, US$7 PT (Analyst: Joel L. Beatty, MD)

For a copy of this research report please contact your Baird advisor

November 14th 2024

Maxim - Positive Survival Data for Efti Triple Combo in 1L NSCLC; Bodes Well for Upcoming P3 Pivotal TACTI-004 Study in Same Setting - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

November 14th 2024

CLSA - Checking-off key points; Positive survival data in triple combo incrementally derisk TACTI-004; Maintain Outperform, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor



E-MAIL UPDATES

registration.

Please fill out the registration form below to receive updates and announcements by e-mail.